Sellas Life Sciences: A $172.5 Million Raise, a 24-Month Survival Median, and the FDA Talks Still to Come
Published on 11/22/2026 at 17:11 | Editorial boerse-global.deSellas Life Sciences closed a public equity offering on Friday, pricing shares at $13.00 apiece and lifting the total gross proceeds to $172.5 million after its banking syndicate exercised in full an option for additional stock. The company's shares finished the session down 8.1%.
The transaction ultimately covered 13,269,231 shares — roughly 13.3 million — a step up from the 11.5 million initially floated when the deal was launched. Underwriters held a 30-day window to pick up the extra stock, and they used all of it. The headline figure is a gross number: discounts, commissions and other expenses still come out of it before any cash reaches the balance sheet.
That distinction matters for anyone weighing what the raise actually does for the company. Sellas had originally targeted $150.0 million in gross proceeds. The enlarged deal strengthens the capital base, but it does so at a cost to existing holders, whose stakes now sit against a larger share count. Dilution is the price of the new equity, and it is a separate question from whether the underlying medicine works.
Should investors sell immediately? Or is it worth buying Sellas Life Sciences?
What the REGAL Readout Actually Showed
The clinical backdrop is the Phase 3 REGAL trial of galinpepimut-S, or GPS, in acute myeloid leukemia. Sellas reported last week that the study hit its primary endpoint of overall survival. Median overall survival came in at 24.0 months on GPS versus 14.7 months on the best available treatment, a gap the company translated into a 41% reduction in the risk of death. The hazard ratio was 0.59, and the p-value was 0.035.
Those are the numbers that give the equity story its substance. They are also not a regulatory green light. Sellas has said it intends to discuss an accelerated submission strategy with the FDA and to prepare a biologics license application in the first half of 2027. Talks and preparations are plans, not approvals — the path from statistical significance to a marketed product still has to be walked.
Two Questions, Not One
Bundling the financing and the trial data into a single verdict gets the analysis wrong in both directions. A stock placement and a clinical readout answer different questions: one is about funding, the other about efficacy. Treating the raise as a validation of the science, or the survival data as a verdict on the balance sheet, conflates two things that deserve to be looked at side by side rather than blended together.
What the pair does describe is a company moving from clinical evidence toward a planned regulatory filing, with a bigger share count along the way. The offering is done. The FDA conversations and the BLA preparation are still ahead. Holding both facts at once — the reported survival benefit and the dilution borne by existing shareholders — is the only honest way to frame the stock from here.
Ad
Sellas Life Sciences Stock: New Analysis - 22 November
Fresh Sellas Life Sciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
